Biomedical subjects

K Furuse

Publications and source records attributed to K Furuse.

201 records · Page 12Linked to original sources

PubMedDate not supplied

Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group.

Twenty-four previously treated patients with refractory or relapsed small cell lung cancer (SCLC) were entered into a prospective, multicenter phase II study. All 24 patients had been pretreated with some form of cisplatin-based chemotherapy. The median time of chemotherapy was 4.2 months (range 1.4-9.4 months). Patients were treated with a dose of 25 mg/m2 of vinorelbine weekly. Twenty-four patients were eligible for response and for toxicity. Partial response was observed in 3 out of 24 eligible patients (12.5%; 95% confidence interval, 2.7-32.4%). All 3 patients who responded had previous chemotherapy including vincristine. The most common toxicity was leukopenia (91.7%, 66.7% in WHO 3-4 grade) and anemia (70.8%, 20.8% in WHO 3 grade). Nonhematological toxicities were moderate and mild. These results support a two-state sequential study design of previously untreated patients for further phase II study in SCLC.

Aged↗

PubMedDate not supplied

Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. West Japan Lung Cancer Group.

Sixty patients with previously untreated non-small cell lung cancer of stages III and IV were treated with a 210 mg/m2 dose of paclitaxel by means of a 3-hour infusion. The objective response rate was 32% (95% confidence interval, 20-45%): 1 complete response and 18 partial responses. The median duration of response was 15 weeks, and the projected median survival duration of all patients was 30 weeks. Grade 3-4 neutropenia occurred in 73% of patients. Other grade 3-4 adverse events included anemia (5%), vomiting/nausea (8%), peripheral edema (2%), alopecia (7%), elevation of AST (2%), peripheral neuropathy (3%), allergic reaction (2%), arthralgia/myalgia (3%), and interstitial pneumonitis (3%). Paclitaxel administered at 210 mg/m2 by means of a 3-hour infusion every 3 weeks demonstrated a notable activity against previously untreated advanced non-small cell lung cancer, with a 32% major response rate. Major toxicity was neutropenia. Hypersensitivity, neurotoxicity, arthralgia/myalgia and cardiac toxicity were mild and easily managed.

Aged↗

PubMedDate not supplied

[Transmission of methicillin-resistant Staphylococcus aureus in a hospital for aged and chronically ill inpatients].

When we tested bacterial contamination in the linens of aged or chronically ill inpatients in a general hospital (114 beds), 11 out of 60 patients were found to have methicillin-resistant Staphylococcus aureus (MRSA). Two of these were MRSA infections. Furthermore, 6 patients mostly elderly and with chronic diseases, were newly infected with MRSA after this surveillance period. So as to clarify the transmission route of MRSA in the hospital, we classified 12 MRSA strains into 4 types by several criteria such as types of coagulase, enterotoxin, toxic-shock syndrome toxin, sensitivity to antibiotics, plasmid contents, and restriction endonuclease digestion patterns of chromosomal DNAs. At the same time, we followed up the movement of patients in wards and conditions of patient contact with medical staff in the hospital. The data obtained revealed a specific correlation between one of the MRSA strains and a doctor, suggesting a contribution from medical staff to the transmission of MRSA in the hospital. It is necessary, therefore, to practice more careful protection procedures against bacterial infection especially in hospitals for aged and chronically ill patients who are vulnerable to various infectious agents.

Adult↗